TY - JOUR
T1 - Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
AU - Rossi, Lorenzo
AU - Biagioni, Chiara
AU - McCartney, Amelia
AU - Migliaccio, Ilenia
AU - Curigliano, Giuseppe
AU - Sanna, Giuseppina
AU - Moretti, Erica
AU - Minisini, Alessandro M
AU - Cinieri, Saverio
AU - Tondini, Carlo
AU - Arpino, Grazia
AU - Bernardo, Antonio
AU - Martignetti, Angelo
AU - Risi, Emanuela
AU - Pestrin, Marta
AU - Boni, Luca
AU - Benelli, Matteo
AU - Biganzoli, Laura
AU - Di Leo, Angelo
AU - Malorni, Luca
PY - 2019/5/29
Y1 - 2019/5/29
N2 - Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.
AB - Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.
U2 - 10.1186/s13058-019-1149-5
DO - 10.1186/s13058-019-1149-5
M3 - Article
C2 - 31142370
VL - 21
SP - 71
JO - Breast Cancer Research
JF - Breast Cancer Research
SN - 1465-5411
IS - 1
ER -